Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Almirall, S.A.
With
Allergan
Age
12–45
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
if women of child-bearing potential, have a negative urine pregnancy test
Willing to use only a non-medicated cleanser and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study
Male or female, 12-45 years of age with body weight between 52 and 88 kg
Diagnosis of acne vulgaris with:
20 to 50 inflammatory lesions (papules, pustules, and nodules) 30 to 100 noninflammatory lesions (open and closed comedones)
No more than 2 nodules on the face
Investigator's Global Assessment (IGA) score of moderate (3) to severe (4)
You may not be if
Dermatological condition of face or facial hair that could interfere with clinical evaluations subjects who have used the following medications (topical refers only to the facial area) will not be eligible:
Within 1 week prior to randomization:
Medicated facial cleansers
Topical acne treatments (other than those listed below)
Within 4 weeks prior to randomization:
Topical retinoids
Topical anti-inflammatories and corticosteroids
Systemic antibiotics
Systemic acne treatments
Within 12 weeks prior to randomization:
Systemic retinoids
Systemic corticosteroids
Pseudomembranous colitis or antibiotic-associated colitis
Hepatitis, liver damage or renal impairment
Clareo Health | Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris
